Arbutus Biopharma Corporation ABUS

ABUS Company Overview

Arbutus Biopharma Corporation (NASDAQ: ABUS) is a clinical-stage biopharmaceutical company focused on developing therapeutics for chronic hepatitis B virus (HBV) infection and other viral diseases. The company operates within the biotechnology and pharmaceutical industries, with a strategic emphasis on antiviral therapies, RNA-based technologies, and immune-modulating approaches. Its primary value drivers are internally developed drug candidates targeting HBV replication and immune restoration, along with intellectual property related to lipid nanoparticle (LNP) delivery technologies. Arbutus has historically generated limited commercial revenue and has relied primarily on licensing agreements, collaboration payments, and capital markets financing to support research and development activities.

The company traces its origins to Tekmira Pharmaceuticals Corporation, which specialized in RNA interference delivery systems. Tekmira later merged with OnCore Biopharma in 2015 and adopted the Arbutus Biopharma name to reflect its broader antiviral development strategy. Since then, Arbutus has concentrated on pursuing a functional cure for chronic HBV through combination therapeutic approaches involving RNA interference, oral antivirals, and immune-based therapies. The company’s positioning has been strengthened by its intellectual property portfolio in LNP technologies, which has been referenced in litigation and licensing activity involving mRNA delivery systems.